Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: captainscotty
Search This Board:
Last Post: 2/6/2016 1:39:09 PM - Followers: 166 - Board type: Free - Posts Today: 1


Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
BHRT - Daily Candlesticks


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
USRM News: Securities Registration Statement (s-1/a) 02/02/2016 04:32:10 PM
USRM News: Amended Statement of Changes in Beneficial Ownership (4/a) 01/15/2016 04:02:06 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 01/04/2016 04:01:45 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 12/28/2015 04:03:47 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 12/21/2015 05:33:23 PM
#16679  Sticky Note Quote LOL, "This is at Nasadaq price days! Captain Kirk 11/04/15 06:31:39 PM
#16979   Everybody is Losing Their F'n Shirts... Poor Man - 02/06/16 01:39:09 PM
#16978   And yet they have the audacity for paying toddski 02/05/16 01:21:42 PM
#16977   .26, Going DOWN IN FLAMES, LOL !! Captain Kirk 02/05/16 10:46:32 AM
#16976   Headed to Zero Poor Man - 02/04/16 08:46:35 PM
#16975   Time to buy? EquityElite 02/04/16 04:07:20 PM
#16974   Epic Disaster Poor Man - 02/03/16 05:41:09 PM
#16973   S-1/a filed, SECOND LAWSUIT, MEGA DILUTION- Captain Kirk 02/03/16 11:14:08 AM
#16972   How is that funny? Investaholic33 02/02/16 12:21:32 PM
#16970   Bid is .39, GOING DOWN, LOL !! Captain Kirk 02/02/16 10:32:36 AM
#16969   Sinking Like a Lead Balloon Poor Man - 01/29/16 08:13:13 PM
#16968   HOLY COW, FREE FALL..AGAIN, LOL !! Captain Kirk 01/29/16 02:51:07 PM
#16967   This POS is DEAD MONEY LOL !! Captain Kirk 01/27/16 11:02:23 PM
#16966   U.S. Stem Cell lawsuit coverage- Captain Kirk 01/26/16 02:21:57 PM
#16965   Just don't get Miguel... Poor Man - 01/21/16 10:33:21 PM
#16964   High rollers here....IMO EquityElite 01/21/16 01:55:34 PM
#16963   CEO Tomas and COLLAPSE OF USRM- Captain Kirk 01/21/16 11:21:23 AM
#16962   Dire Straits for this Stock Poor Man - 01/20/16 09:44:50 PM
#16961   WIPE OUT- kinda "smelled" that one coming: Captain Kirk 01/20/16 04:44:26 PM
#16960   Someone still propping up the Ask, LOL?? Captain Kirk 01/20/16 10:49:48 AM
#16959   toddski, HOLY COW?? Captain Kirk 01/15/16 08:16:39 PM
#16958   With the amount of money Murphy spent here toddski 01/15/16 06:33:58 PM
#16957   The plaintiff's claims makes this suit sound a Gaintrader 01/15/16 01:03:39 AM
#16956   Falling Bid/Ask, TANKING NOW, LOL !! Captain Kirk 01/14/16 11:37:13 AM
#16955   Man Bioheart is Stupid Poor Man - 01/10/16 03:06:52 PM
#16954   U.S. Stem Cell SUED, MAJOR LAWSUIT !! Captain Kirk 01/09/16 04:56:37 PM
#16953   Form-4 buying stops, PRICE COLLAPSES, LOL !! Captain Kirk 01/05/16 12:07:57 PM
#16952   POS ends 2015 RED, a PENNY STOCK, LOL !! Captain Kirk 01/03/16 07:44:01 PM
#16951   $USRM Holding in the 0.80's...:-}WHO KNOWS? captainscotty 01/03/16 06:37:07 PM
#16950   Inter-esting.... EquityElite 12/30/15 05:10:00 PM
#16949   This will snowball downhill.... Poor Man - 12/30/15 02:09:30 PM
#16948   Bingo !! ANOTHER Form-4, LOL !!! Captain Kirk 12/28/15 04:44:30 PM
#16947   Looks like Form-4 buying, LOL !!! Captain Kirk 12/23/15 10:48:45 AM
#16946   Almost all buys today??? Poor Man - 12/22/15 08:38:20 PM
#16945   Quote LOL, "Almost all buys today?" Captain Kirk 12/22/15 01:27:23 PM
#16944   Almost all buys today? EquityElite 12/22/15 01:04:33 PM
#16943   Falling Bid, FALLING ASK, LOL !! Captain Kirk 12/22/15 12:46:13 PM
#16942   Cash Machine (No More) Poor Man - 12/21/15 07:27:35 PM
#16941   Mike buy's like $1K worth, LOL !! Form-4: Captain Kirk 12/21/15 06:03:07 PM
#16940   Spread at like 30% again, LOL !! Captain Kirk 12/21/15 10:28:11 AM
#16939   This is looking interesting... EquityElite 12/19/15 06:42:19 PM
#16938   $USRM Yup Kirk...The MM's are BRUTAL look for captainscotty 12/19/15 11:17:16 AM
#16937   Cambridge researchers study -- stem cells as safer saratg 12/18/15 02:43:59 AM
#16936   200 shares DOWN 25%, LOL !!! Captain Kirk 12/17/15 10:18:53 AM
#16935   Stem cell clothing? EquityElite 12/17/15 09:07:25 AM
#16934   "What the freak does this even mean, "Biotech Poor Man - 12/16/15 10:44:56 PM
#16933   This must be a joke... LOL !!! Captain Kirk 12/16/15 09:46:14 PM
#16932   This must be a joke... Poor Man - 12/16/15 07:53:43 PM
#16931   Wild ride here in my opinion. I am EquityElite 12/16/15 03:43:10 PM
#16930   Very Thoughtful respond. Thanks ihubmoney 12/16/15 12:36:11 PM
#16929   ihubmoney, Just "the usual" if I had to guess. Captain Kirk 12/16/15 12:32:37 PM